Volume : 09, Issue : 06, June – 2022
Title:
55.DEVELOPMENT AND STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF METFORMIN HCL AND TENELIGLIPTIN HBR HYDRATE IN BULK AND PHARMACEUTICAL DOSAGE FORM
Authors :
Mr.Satish S Mane*, Mr. Mahesh S Mhaske
Abstract :
The objective of the current work is to develop a simple, efficient, economical and compatible RP-HPLC method for the analysis of Metformin HCL and Tenegliptin hydrobromide in bulk and pharmaceutical dosage form dosage forms. Samples were separated on Grace C8 (250mm x 4.6 id. particle size: 5 (micron) column with mobile phase composed of OPA and acetonitrile (pH 3.00) The method was carried out on Grace C8 (250mm x 4.6 i.d. particle size: 5 micron) using 0.1% OPA and acetonitrile in the ratio of 70:30 v/v with adjusted pH 3 at flow rate 0.9 mL/min. The wavelength of Metformin HCL and Teneligliptin HBr Hydrate at 246 nm was found to be appropriate. The linearity range was obtained in the concentration of 50-250 μg/mL Metformin HCL and 02-10 μg/mL Teneligliptin HBr Hydrate respectively. The retention time of Metformin HCL and Teneligliptin HBr Hydrate was found to be 2.395 ± 0.2 min and 2.891± 0.2 min respectively. The developed method was found be accurate, robust and sensitive which can be used for estimation of combination of Metformin HCL and Teneligliptin HBr Hydrate in bulk and pharmaceutical dosage form.
Keywords: Metformin HCL and Tenegliptin hydrobromide Phenomenex Grace C8 Column, Detection, RP HPLC
Cite This Article:
Please cite this article in press Satish S Mane et al, Development And Stability Indicating RP-HPLC Method For Simultaneous Estimation Of Metformin Hcl And Teneligliptin Hbr Hydrate In Bulk And Pharmaceutical Dosage Form., Indo Am. J. P. Sci, 2022; 09(6).,
Number of Downloads : 10
References:
1. Thus from the above result of the individual test is conclude that the analytical method is validated and found to be satisfactory. Mendham J, Denny RC. Barns JD. Vogel’s text book for quantitative chemical analysis. 2001;06:297-305.
2. Oona M et al. A textbook of validation of analytical method for pharmaceutical analysis. Mourne training publisher service 2005;01:1-2.
3. Hong DD, Shah M et al. Development and validation of HPLC stability indicating method f drug. 2000:329-84.
4. Bakshi M, Singh M et al. Development of validated stability indicating assay methods critical review. 2002;28(6):1011-1040.
5. Canner’s KA. A text book f pharmaceutical analysis. CBS publication and distributors Pvt.Ltd., New Delhi, 2001;03:3-6.
6. Chatwal GR, Anand SK. Instrumental Methods of Chemical Analysis. 5th edition. Himalaya Publishing House. Delhi. 2007:2.150.
7. Gorog, Sandor. Drug safety drug quality, drug analysis. Journal of pharmaceutical and biological analysis, 2008:247-53.
8. Wong AW. Assay and stability Testing. handbook of pharmaceutical analysis by HPLC. 2005;01:335-39.
9. Meleager. Critical regulatory requirement for a stability program. Handbook of stability testing in pharmaceutical development. 2009:9-19.
10. Khan, Hamid et al. Stability testing of pharmaceutical product – comparison of stability testing guideline. Journal of applied pharmaceutical science, 2012:129-38
11. Guidance for industry, Q2 (R1) validation of analytical procedure : Methodology, U.S department f health and human services, Food and drug administration, centre for the drug evaluation and research (CDER),centre for biologics evaluation and research (CBER), international conference of harmonization (ICH), Geneva, November-2015.
12. Bajajet. Stability testing of pharmaceutical products, Journal of applied pharmaceutical science, 2012:129-38.
13. Arstensen C. Introductory overview, drug stability: principles and practices, Third edition, 2002:2-17.
14. Yoshioka, Sumie, Valentino J. Chemical stability of drug substance. stability of drug and dosage form, 2000:3-135.
15. Acharaya MM. Pharmaceutical stability testing and studies: an overview. The eastern pharmacist 1999:31-36.
16. Alsante, Karen M. The role of degradant profiling in active pharmaceutical ingredients and drug product. Advanced drug delivery review, 2007:29-37.
17. Klick, Silke. Toward a generic approach for stress testing of drug substance and drug product, Pharmaceutical technology, 2009:48-60.
18. Gupta, Krishna R. Stability indicating RP-HPLC method for simultaneous determination of Atorvastatin and nicotinic acid from their combined dosage forms, Eurasian journal of analytical chemistry, 2009:294-303.
19. Chow, Shein-Chung. Introduction of statistical design and analysis of stability studies. 2007:1-3.
20. Reynolds, Dan W. Available guidance and best practice for conducting forced degradation studies. Pharmaceutical technology 2002: 48-56.
21. International conference of harmonization (2000) draft received guidance on impurities in new drug substance, Federal Register Q3A(R), (139);45085
22. International conference of harmonization (2000) draft received guidance on impurities in new drug substance, Federal Register Q3B(R), (139); 44791
23. International conference of harmonization (1997) impurities, Q3C- guideline for residual solvent, Q3C, Federal Register 62 (247);67377.
24. International conference of harmonization (1999) specification Q6A-test procedure and acceptance criteria for new drug substance and new drug product. Chemical substance, (146);67488.
25. Ahuja S. Impurities evaluation of pharmaceutical (1998);142-150.
26. ICH, Stability testing of new drug substance and product. International conference of Hormonization, Geneva, (1993).
27. ICH,Quality of biotechnological product, Stability testing of
biotechnological/biological products. International conference of Hormonization, Geneva, (1995).
28. ICH, Impurities in new drug products, International conference of Hormonization, Geneva, (1996).
29. Perzborn E, Strassburger J, Wilmen A. In vitro and in vivo studies of the novel antithrombotic agent. BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost., (2005); 514–521.
30. Depasse F, Busson J, Mnich J. Effect of BAY 59-7939—a novel, oral, direct Factor Xa inhibitor—on clot-bound Factor Xa activity in vitro. [abstract no. P1104]. J Thromb Haemost. (2005); 3(Suppl 1).
31. Kubitza D, Becka M, Voith B. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412–421.
32. International Conference on Harmonisation. ICH E14 The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04); 2005.
33. Kubitza D, Becka M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–880.
34. Cardiovascular and Renal Drugs Advisory Committee. FDA Advisory Committee Briefing Document; 2009.
35. European Medicines Agency. CHMP assessment report for Xarelto; 2008.
36. Khopkar SM. Basic Concept of Analytical Chemistry. 2nd ed. New Delhi: New Age International Ltd. Publishers; 1998:178-179.
37. Christen GD. Analytical Chemistry. 5th ed. John Wiley and Sons; 2003;35-42,131132.
38. Jeffery GH, Bassett J, Mendham J, Denney RC. Vogel’s Textbook of Quantitative Chemical Analysis. 5th ed. New York: John Wiley and Sons, Inc.; 1989:3-4.
39. Skoog DA, Holler FJ, Crouch SR. Principle of Instrumental Analysis. 5th ed.
Thomson Brooks/Cole.; 2004:1-2, 678-688.
40. Swarbrick J, Boylan JC. Encyclopedia of Pharmaceutical Technology. Vol-1. 3rd ed. New York: Marcel Dekker Inc.; 1997:538-540.